Completed PHASE1 INTERVENTIONAL 2-arm NCT02235727

Safety and Tolerability of GBR 900 in a Single Ascending Dose Study in Healthy Subjects

A Phase 1, Double-Blind, Randomised, Placebo-Controlled, Study to Evaluate the Safety and Pharmacokinetics of GBR 900 in Adult Healthy Volunteers

Sponsor: Glenmark Pharmaceuticals Ltd. India

Conditions Healthy

Interventions GBR 900 Placebo

Updated 6 times since 2017 Last updated: Jan 23, 2017 Started: Jul 31, 2014 Primary completion: Nov 30, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Glenmark Pharmaceuticals Ltd. India and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Data source: Glenmark Pharmaceuticals Ltd. India

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeds, United Kingdom